IBS Inc.

The Biosensor Platform

A Platform for Multiple Diagnostic Tests

Innovative Organic Thin Film Transistor (OTFT) Technology.

The Biosensor Platform is a small, printable organic strip designed to put the power of accurate, timely diagnosis in the hands of patients and their primary health practitioners.

The Biosensor Platform uses Organic Thin Film Transistor (OTFT) technology, which can be printed at scale and low cost. 


The Saliva Glucose Biosensor

By altering the detection element (region A) depending on the specific analyte of interest, we can produce a complete portfolio of non-invasive, real-time, saliva-based diagnostic tests.

Because both the core OTFT sensing element and the mechanism of action remain the same, tests developed from the Biosensor Platform have the potential to be printed at scale and low cost.

The University of Newcastle

Behind the Technology

The biosensor was invented at the Priority Research Centre for Organic Electronics at The University of Newcastle, Australia.

The Centre for Organic Electronics is the first of its kind in Australia. It is an exciting new initiative focusing on the development of new electronic devices at the intersection between semiconductors and plastics.

The Centre focuses on the scientific challenges in the development of organic electronics, with massive potential for the next generation of environmentally friendly energy sources, photonics and biosensors.

Play Video

Our Journey

The Story of the Biosensor


Research Begins

Professor Paul Dastoor and the University of Newcastle team begin research into conducting polymers.


IP Filed

IP for Organic Thin-Film Transistor (OTFT) technology filed.



Detection of saliva-range glucose concentrations using organic thin-film transistors”, Applied Physics Letters, 105, 043303 (2014).

US Patent Granted

Patent: US 9,766,199B2
Original IP protected to 2033, with more patents to be filed. Ongoing development by scientific team.

GBS Inc. Established

Leadership team established for GBS Inc.


Biosensor Platform Pipeline Extended

GBS Inc. announces extension of research and development of biosensor for additional indications including cancer, allergen and hormone biomarkers.


China Patent Granted

Patent: CN201380022888.2



GenomeWeb acknowledges the Saliva Glucose Biosensor as leading the race to the “holy grail” of life sciences.

COVID-19 Antibody Program

Collaboration with Wyss Institute for Biologically Inspired Engineering at Harvard University commences for COVID-19 antibody program.



GBS Inc. enters sponsored research agreement with Johns Hopkins Bloomberg School of Public Health to accelerate development of saliva-based diagnostic tests.

Government Grant

GBS awarded $4.7 Million Australian Federal Government Science Grant to manufacture Biosensor technology.

Clinical Trials

GBS Inc. announces institutional review board approval to initiate clinical trial at Sutter Health Mills-Peninsula Medical Center.



GBS Inc. initiates manufacturing on the University of Newcastle Australia campus.


Clinical Study

GBS Inc. completes sample collection and analysis of glucose in oral fluid and blood samples from clinical study at the Diabetes Research Institute of Sutter Health’s Mills-Peninsula Medical Center (MPMC) in San Mateo, California.


GBS Inc. Initiates Company Name Change to Intelligent Bio Solutions Inc.

Name change reflects the company's expanding portfolio of intelligent, efficient, and non-invasive testing technologies and products.



Intelligent Bio Solutions successfully completes Milestone 7 at the University of Newcastle. Results showed a record 4x improvement in TTR, enabling the biosensor to return test results in under one minute.

Sign Up

Subscribe to receive the latest news and updates from Intelligent Bio Solutions.